Publication: Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma.
cris.virtualsource.author-orcid | 3ffc609d-4653-413a-a80f-2bf6c2b71f47 | |
dc.contributor.author | Ahmed, Sairah | |
dc.contributor.author | Kanakry, Jennifer A | |
dc.contributor.author | Ahn, Kwang W | |
dc.contributor.author | Litovich, Carlos | |
dc.contributor.author | Abdel-Azim, Hisham | |
dc.contributor.author | Aljurf, Mahmoud | |
dc.contributor.author | Bacher, Vera Ulrike | |
dc.contributor.author | Bejanyan, Nelli | |
dc.contributor.author | Cohen, Jonathon B | |
dc.contributor.author | Farooq, Umar | |
dc.contributor.author | Fuchs, Ephraim J | |
dc.contributor.author | Bolaños-Meade, Javier | |
dc.contributor.author | Ghosh, Nilanjan | |
dc.contributor.author | Herrera, Alex F | |
dc.contributor.author | Hossain, Nasheed M | |
dc.contributor.author | Inwards, David | |
dc.contributor.author | Kanate, Abraham S | |
dc.contributor.author | Martino, Rodrigo | |
dc.contributor.author | Munshi, Pashna N | |
dc.contributor.author | Murthy, Hemant | |
dc.contributor.author | Mussetti, Alberto | |
dc.contributor.author | Nieto, Yago | |
dc.contributor.author | Perales, Miguel-Angel | |
dc.contributor.author | Romee, Rizwan | |
dc.contributor.author | Savani, Bipin N | |
dc.contributor.author | Seo, Sachiko | |
dc.contributor.author | Wirk, Baldeep | |
dc.contributor.author | Yared, Jean A | |
dc.contributor.author | Sureda, Ana | |
dc.contributor.author | Fenske, Timothy S | |
dc.contributor.author | Hamadani, Mehdi | |
dc.date.accessioned | 2024-10-28T17:17:24Z | |
dc.date.available | 2024-10-28T17:17:24Z | |
dc.date.issued | 2019-09 | |
dc.description.abstract | Classic Hodgkin lymphoma (cHL) patients with relapsed or refractory disease may benefit from allogeneic hematopoietic cell transplantation (allo-HCT), but many lack a matched sibling donor (MSD). Herein, we compare outcomes of 2 reduced-intensity conditioning (RIC) HCT platforms in cHL: T cell-replete related donor haploidentical (haplo) HCT with a post-transplant cyclophosphamide (PTCy)-based approach versus an MSD/calcineurin inhibitor (CNI)-based approach. The study included 596 adult patients who underwent a first RIC allo-HCT for cHL between 2008 and 2016 using either a haplo-PTCy (n = 139) or MSD/CNI-based (n = 457) approach. Overall survival (OS) was the primary endpoint. Secondary endpoints included acute graft-versus-host disease (aGVHD) and chronic GVHD (cGVHD), nonrelapse mortality (NRM), relapse/progression, and progression-free survival (PFS). On multivariate analysis, there was no significant difference between haplo/PTCy and MDS/CNI-based approaches in terms of OS (hazard ratio [HR], 1.07; 95% confidence interval [CI], .79 to 1.45; P = .66) or PFS (HR, .86; 95% CI, .68 to 1.10; P = .22). Haplo/PTCy was associated with a significantly higher risk of grades II to IV aGVHD (odds ratio [OR], 1.73, 95% CI, 1.16 to 2.59; P = .007), but the risk of grades III to IV aGVHD was not significantly different between the 2 cohorts (OR, .61; 95% CI, .29 to 1.27; P = .19). The haplo/PTCy platform provided a significant reduction in cGVHD risk (HR, .45; 95% CI, .32 to .64; P < .001), and a significant reduction in relapse risk (HR, .74; 95% CI, .56 to .97; P = .03). There was a statistically nonsignificant trend toward higher NRM with a haplo/PTCy approach (HR, 1.65; 95% CI, .99 to 2.77; P = .06). Haplo/PTCy-based approaches are associated with lower incidences of cGVHD and relapse, with PFS and OS outcomes comparable with MSD/CNI-based approaches. There was a leaning toward higher NRM with a haplo/PTCy-based platform. These data show that haplo/PTCy allo-HCT in cHL results in survival comparable with MSD/CNI-based allo-HCT. | |
dc.description.numberOfPages | 10 | |
dc.description.sponsorship | Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor | |
dc.identifier.doi | 10.7892/boris.133199 | |
dc.identifier.pmid | 31132455 | |
dc.identifier.publisherDOI | 10.1016/j.bbmt.2019.05.025 | |
dc.identifier.uri | https://boris-portal.unibe.ch/handle/20.500.12422/182095 | |
dc.language.iso | en | |
dc.publisher | Elsevier | |
dc.relation.ispartof | Biology of blood and marrow transplantation | |
dc.relation.issn | 1083-8791 | |
dc.relation.organization | DCD5A442C055E17DE0405C82790C4DE2 | |
dc.subject | Allogeneic transplantation Alternative donor Haploidentical transplantation Hodgkin lymphoma | |
dc.subject.ddc | 600 - Technology::610 - Medicine & health | |
dc.title | Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. | |
dc.type | article | |
dspace.entity.type | Publication | |
dspace.file.type | text | |
oaire.citation.endPage | 1868 | |
oaire.citation.issue | 9 | |
oaire.citation.startPage | 1859 | |
oaire.citation.volume | 25 | |
oairecerif.author.affiliation | Universitätsklinik für Hämatologie und Hämatologisches Zentrallabor | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.contributor.role | creator | |
unibe.date.licenseChanged | 2019-11-13 15:00:43 | |
unibe.description.ispublished | pub | |
unibe.eprints.legacyId | 133199 | |
unibe.journal.abbrevTitle | BIOL BLOOD MARROW TR | |
unibe.refereed | TRUE | |
unibe.subtype.article | journal |
Files
Original bundle
1 - 1 of 1
- Name:
- Lower Graft.pdf
- Size:
- 680.67 KB
- Format:
- Adobe Portable Document Format
- File Type:
- text
- License:
- publisher
- Content:
- published